198 related articles for article (PubMed ID: 20686826)
21. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
Shitara Y; Maeda K; Ikejiri K; Yoshida K; Horie T; Sugiyama Y
Biopharm Drug Dispos; 2013 Jan; 34(1):45-78. PubMed ID: 23115084
[TBL] [Abstract][Full Text] [Related]
22. Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
Tsujimoto M; Hatozaki D; Shima D; Yokota H; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Ther Apher Dial; 2012 Dec; 16(6):580-7. PubMed ID: 23190519
[TBL] [Abstract][Full Text] [Related]
23. Involvement of organic anion transporting polypeptide 1a5 (Oatp1a5) in the intestinal absorption of endothelin receptor antagonist in rats.
Tani T; Gram LK; Arakawa H; Kikuchi A; Chiba M; Ishii Y; Steffansen B; Tamai I
Pharm Res; 2008 May; 25(5):1085-91. PubMed ID: 17957449
[TBL] [Abstract][Full Text] [Related]
24. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
26. Transport Properties of Statins by Organic Anion Transporting Polypeptide 1A2 and Regulation by Transforming Growth Factor-
Ronaldson PT; Brzica H; Abdullahi W; Reilly BG; Davis TP
J Pharmacol Exp Ther; 2021 Feb; 376(2):148-160. PubMed ID: 33168642
[TBL] [Abstract][Full Text] [Related]
27. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
28. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.
Wu LX; Guo CX; Chen WQ; Yu J; Qu Q; Chen Y; Tan ZR; Wang G; Fan L; Li Q; Zhang W; Zhou HH
Br J Clin Pharmacol; 2012 May; 73(5):750-7. PubMed ID: 22114872
[TBL] [Abstract][Full Text] [Related]
30. Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling.
Mao J; Doshi U; Wright M; Hop CECA; Li AP; Chen Y
CPT Pharmacometrics Syst Pharmacol; 2018 Apr; 7(4):251-258. PubMed ID: 29388346
[TBL] [Abstract][Full Text] [Related]
31. Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake.
Wen F; Shi M; Bian J; Zhang H; Gui C
Pharm Biol; 2016; 54(2):293-302. PubMed ID: 25858254
[TBL] [Abstract][Full Text] [Related]
32. Regional absorption of fexofenadine in rat intestine.
MacLean C; Moenning U; Reichel A; Fricker G
Eur J Pharm Sci; 2010 Dec; 41(5):670-4. PubMed ID: 20869437
[TBL] [Abstract][Full Text] [Related]
33. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Niemi M; Schaeffeler E; Lang T; Fromm MF; Neuvonen M; Kyrklund C; Backman JT; Kerb R; Schwab M; Neuvonen PJ; Eichelbaum M; Kivistö KT
Pharmacogenetics; 2004 Jul; 14(7):429-40. PubMed ID: 15226675
[TBL] [Abstract][Full Text] [Related]
34. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.
Seithel A; Eberl S; Singer K; Auge D; Heinkele G; Wolf NB; Dörje F; Fromm MF; König J
Drug Metab Dispos; 2007 May; 35(5):779-86. PubMed ID: 17296622
[TBL] [Abstract][Full Text] [Related]
35. Intestinal absorption mechanism of rotundic acid: Involvement of P-gp and OATP2B1.
Shang H; Sun Y; Wang Z; Zhou Y; Yang H; Ci X; Cui T; Xia Y; Gu Y; Liao M; Li Q; Si D; Liu C
J Ethnopharmacol; 2022 May; 289():115006. PubMed ID: 35051604
[TBL] [Abstract][Full Text] [Related]
36. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
37. Transporter-mediated intestinal absorption of fexofenadine in rats.
Kikuchi A; Nozawa T; Wakasawa T; Maeda T; Tamai I
Drug Metab Pharmacokinet; 2006 Aug; 21(4):308-14. PubMed ID: 16946558
[TBL] [Abstract][Full Text] [Related]
38. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
[TBL] [Abstract][Full Text] [Related]
39. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1.
Mandery K; Bujok K; Schmidt I; Keiser M; Siegmund W; Balk B; König J; Fromm MF; Glaeser H
Biochem Pharmacol; 2010 Dec; 80(11):1746-53. PubMed ID: 20797388
[TBL] [Abstract][Full Text] [Related]
40. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
Igel M; Arnold KA; Niemi M; Hofmann U; Schwab M; Lütjohann D; von Bergmann K; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2006 May; 79(5):419-26. PubMed ID: 16678544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
